Gilead Sciences Deal History & Licensing Activity
Gilead Sciences is a large pharma headquartered in US. Over the past three years, Gilead Sciences has been involved in 16 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 50 active clinical trials, primarily in Infectious.
Deals (12mo)
8
Active Trials
50
Top Modality
Small Molecules
Focus Area
Infectious
Gilead Sciences Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Gilead Sciences in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| GS-1179 and GS-5366 | Assembly Biosciences | Small Molecules | Phase 1 | collaboration | Sep 8, 2026 |
| gamgertamig (OM336) | Lakefront Biotherapeutics | Bispecific Antibodies | Phase 1 | collaboration | Jun 4, 2026 |
| TUB-040 | Tubulis | ADC | Phase 2 | acquisition | Apr 7, 2026 |
| OM336 (gamgertamig) | Galapagos NV | Bispecific Antibodies | Phase 1 | collaboration | Mar 24, 2026 |
| OM336 (gamgertamig, BCMAxCD3 TCE) | Gilead | Other | Preclinical | acquisition | Mar 23, 2026 |
| anito-cel | Arcellx | CAR-T | Phase 3 | acquisition | Feb 23, 2026 |
| GH31 | Genhouse Bio | Small Molecules | Phase 1 | license | Feb 21, 2026 |
| ABI-5366 + ABI-1179 (HSV) | Assembly Biosciences | Small Molecules | Phase 1 | license | Dec 22, 2025 |
Gilead Sciences Pipeline Focus
Therapeutic areas and modalities where Gilead Sciences is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Gilead Sciences Strategic Signals
Key indicators of Gilead Sciences's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Gilead Sciences Clinical Pipeline
Gilead Sciences has 50 active clinical trials across 8 development phases.
9
Unknown
5
Not Applicable
3
Phase 4
10
Phase 1
1
Phase 1/2
11
Phase 2
4
Phase 2/3
7
Phase 3
See How Your Asset Matches Gilead Sciences's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Gilead Sciences Licensing & Deal Activity
Gilead Sciences is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 16 deals over the past three years, Gilead Sciences ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Gilead Sciences include Infectious (22 deals and trials), Solid Tumors (12 deals and trials), Oncology (11 deals and trials), and Immunology (7 deals and trials). In terms of modality, Gilead Sciences has shown particular interest in small molecules, bispecific antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Gilead Sciences and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Gilead Sciences's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.